UNSPSC 51352104: Dienestrol diacetate

This classification denotes a non-steroidal estrogen with the molecular formula C22H22O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D20D148WPQ, chemically known as phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, diacetate, (e,e)-, but more generally known as dienestrol diacetate, which bears US NIH Compound Identifier 5357580. European Medicines Agency schedules dienestrol diacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07107MIG.

Most nations, for tariff purposes, schedule dienestrol diacetate under HS 29072900. SMILES: C/C=C(/C(=C/C)/C1CCC(CC1)OC(=O)C)\C2CCC(CC2)OC(=O)C.

UNSPSC 51352104 Dienestrol diacetate is a Commodity code covering pharmaceutical active ingredients and finished products procured through cooperative purchasing agreements for distribution across state and local government health systems. State and local procurement under this code centers on multi-source generic pharmaceuticals and over-the-counter products supplied through established wholesaler networks, where issuing bodies specify products by National Drug Code, strength, dosage form, and packaging configuration. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary procurement vehicle for this category, extending purchasing power across multiple participating states including Oregon. Vendors must maintain current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, hold contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and carry substantial insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability coverage.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802) is the primary recent opportunity under this code, with responses due March 26, 2026 and contract effectiveness July 1, 2026. Evaluation criteria emphasize price competitiveness (75 percent weight), with 10 percent allocated to fixed pricing for the contract term, 5 percent to administrative fee compliance, 5 percent to EDI capability, and 5 percent to agreement with a 3 percent administrative fee structure. Vendors must submit comprehensive product information in CSV format through the ePro procurement system and demonstrate pricing flexibility across flat price, net price formats (NF30, NF60, NF90), and WAC-minus structures. The procurement targets product availability by May 15, 2026, with contract terms of two years for new responders and extensions at MMCAP's sole discretion, while incumbent amendments align through June 30, 2028. MMCAP reserves discretion for sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.